Stock Market Daily: Intellia Therapeutics stock has undergone multiple analysts rating changes in the recent past. Intellia Therapeutics, Inc. (NTLA) Plans and Analysts Expectations Intellia Therapeutics, Inc. (NASDAQ:NTLA) went up by 4.66% from its latest closing price when compared to the 1-year high value of $24.32 and move down -10.55%, while NTLA stocks collected +1.90% of gains with the last five trading sessions.
See what's happening in the market right now with MarketBeat's real-time news feed. The average price we get from analysts is $28.05 which is $6.65 above current price. In addition, Intellia Therapeutics, Inc. saw 49.97% in overturn over the period of a single year with a tendency to cut further gains.Intellia Therapeutics, Inc. (NASDAQ: NTLA) The 36 Months beta value for NTLA stocks is at 1.73, while of the analysts out of 0 who provided ratings for Intellia Therapeutics, Inc. stocks as a “buy” while as overweight, rated it as hold and as sell. The institutional investor owned 1,724,683 shares of the company’s stock after buying an additional 31,214 shares during the period. You have already added five stocks to your watchlist. In oppose to the moving average for the last 50 days, trading by +66.04% upper at the present time.NTLA stocks went up by 1.90% for the week, with the monthly jump of 8.59% and a quarterly performance of 97.49%, while its annual performance rate touched 37.33%. State Street […] The net margin for Intellia Therapeutics, Inc. stands at -230.92. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA) has named David Lebwohl , M.D., as its new executive vice president and chief medical officer. Multiple other drug candidates are expected to earn regulatory permission in 2021 for clinical trials. Intellia Therapeutics, Inc. engages in the development of gene editing-based therapies. There's a long way to go for Intellia Therapeutics, but investors will finally have tangible milestones to look forward to in the coming quarters.Today's news might not completely remove doubt from the minds of investors, but it serves as a reminder that Regeneron Pharmaceuticals remains a committed development partner. Total capital return value is set at -37.57, while invested capital returns managed to touch -35.52.
, April 28, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics usingCAMBRIDGE, Mass. Returns as of 07/30/2020. Learn about financial terms, types of investments, trading strategies and more.View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks.
The receivables turnover for Intellia Therapeutics, Inc. is 7.09 with the total asset turnover at the value of 0.13. Equity return holds the value -40.90%, with -32.50% for asset returns.In the course of the last 5 trading sessions, NTLA went up by +1.90%, which changed the moving average for the period of 200 days to the total of +50.27% of gains for the stock in comparison to the 20-day moving average settled at $20.83. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist.Looking for new stock ideas?
CAMBRIDGE, Mass. View our full suite of financial calendars and market data tables, all for free.Learn everything you need to know about successful options trading with this three-part video course.Receive a free world-class investing education from MarketBeat.
Want to see which stocks are moving? , June 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , announced today that it has commenced an underwritten public© Intellia Therapeutics 2020Intellia Therapeutics and the Intellia Therapeutics logo are registered trademarks with the U.S. Patent & Trademark Office.CAMBRIDGE, Mass. View which stocks are hot on social media with MarketBeat's trending stocks report.Identify stocks that meet your criteria using seven unique stock screeners. , April 30, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , will present its first quarter 2020 financial results and operationalCAMBRIDGE, Mass.
The rating they have provided for NTLA stocks is “Neutral” according to the report published on February 14, 2020.The stock volatility was left at 7.89%, however, within the period of a single month, the volatility rate increased by 6.19%, while the shares sank at the distance of -1.48% for the moving average in the last 20 days. Fintech Innovation a Solid Alternative to Established Options OLD National Bancorp IN Increases Stock Position in Genpact Limited (NYSE:G) McKesson Co. (NYSE:MCK) Shares Sold by … NTLA currently has a short float of 21.66% and public float of 46.30M …